Aug 5 (Reuters) - U.S. drugmaker Pfizer ( PFE ) raised
its full-year profit forecast on Tuesday, boosted by robust
demand for its heart disease drug, Vyndaqel, and some older
treatments.
The drugmaker now expects to earn $2.90 to $3.10 per share
on an adjusted basis in 2025, compared with its previous
expectations of $2.80 to $3.00 per share.